The past 10 years have seen the publication of results from several multicentre clinical trials in primary and systemic sclerosis (SSc)-related Raynaud phenomenon. The publication of these studies has occurred as a result of new insights into the pathogenesis of Raynaud phenomenon, which are directing new treatment approaches, and increased international collaboration between clinicians and scientists. Although the pathogenesis of Raynaud phenomenon is complex, abnormalities of the blood vessel wall, of neural control mechanisms and of intravascular (circulating) factors are known to interact and contribute. Key players relevant in drug development include nitric oxide, endothelin-1, alpha adrenergic receptor activation, abnormal signal transduction in vascular smooth muscle, oxidative stress and platelet activation. The main advances in diagnosis have been a clearer understanding of autoantibodies and of abnormal nailfold capillary patterns as independent predictors of SSc, and widespread use and increased availability of capillaroscopy. The ultimate aim is to translate the advances made in the pathophysiology and early diagnosis into development of treatments to prevent and reverse digital vascular dysfunction and injury. This Review provides an update of the pathogenesis, diagnosis and treatment of Raynaud phenomenon. Current and future treatment approaches are discussed, and some key unanswered questions are highlighted.
When a patient presents with Raynaud phenomenon, the clinician should first decide whether the condition is primary (idiopathic) or secondary to an underlying cause, which might require specific treatment
Primary Raynaud phenomenon is vasospastic and does not progress to irreversible tissue injury; conversely, systemic sclerosis (SSc)-related Raynaud phenomenon can lead to digital ulceration and gangrene, which require urgent medical intervention
Although the pathogenesis of Raynaud phenomenon is complex and incompletely understood, progress is being made and new insights are directing novel approaches to treatment
Abnormalities of the blood vessel wall, of neural control mechanisms, and of intravascular (circulating) factors can all contribute to the pathogenesis of Raynaud phenomenon
In patients with Raynaud phenomenon, presence of SSc-specific autoantibodies and abnormal nailfold capillary pattern are independent predictors of an underlying SSc-spectrum disorder
New treatment approaches for Raynaud phenomenon include phosphodiesterase inhibitors and, for patients with SSc and recurrent digital ulcers, endothelin-1 receptor antagonists
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series
Pediatric Rheumatology Open Access 20 August 2022
A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis
Clinical Reviews in Allergy & Immunology Open Access 07 March 2022
Evaluation of thermal sensitivity is of potential clinical utility for the predictive, preventive, and personalized approach advancing metabolic syndrome management
EPMA Journal Open Access 18 February 2022
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Maricq, H. R. et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J. Rheumatol. 24, 879–889 (1997).
Silman, A., Holligan, S., Brennan, P. & Maddison, P. Prevalence of symptoms of Raynaud's phenomenon in general practice. BMJ 301, 590–592 (1990).
Suter, L. G., Murabito, J. M, Felson, D. T. & Fraenkel, L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum. 52, 1259–1263 (2005).
Carpentier, P. H., Satger, B., Poensin, D. & Maricq, H. R. Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population. J. Vasc. Surg. 44, 1023–1028 (2006).
Walker, U. A. et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann. Rheum. Dis. 68, 856–862 (2009).
Hartmann, P., Mohokum, M. & Schlattmann, P. The association of Raynaud's syndrome with rheumatoid arthritis—a meta-analysis. Clin. Rheumatol. 30, 1013–1019 (2011).
Raynaud, M. Local Asphyxia and Symmetrical Gangrene of the extremities 1862, and New researches on the Nature and Treatment of Local Asphyxia of the Extremities, 1874. (New Syndenham Society, London, 1888).
Lewis, T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 15, 7–11 (1929).
Charkoudian, N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol. 109, 1221–1228 (2010).
Johnson, J. M. & Kellogg, D. L. Local thermal control of the human cutaneous circulation. J. Appl. Physiol. 109, 1229–1238 (2010).
Herrick, A. L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44, 587–596 (2005).
Gunawardena, H., Harris, N. D., Carmichael, C. & McHugh, N. J. Maximum blood flow and microvascular regulatory responses in systemic sclerosis. Rheumatology (Oxford) 46, 1079–1082 (2007).
Rossi, M. et al. Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients. Rheumatology (Oxford) 47, 1012–1017 (2008).
Wigley, F. M. Vascular disease in scleroderma. Clin. Rev. Allergy Immunol. 36, 150–175 (2009).
Cotton, S. A., Herrick, A. L., Jayson, M. I. & Freemont, A. J. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J. Pathol. 189, 273–278 (1999).
Ibba-Manneschi, L. et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum. 54, 202–213 (2006).
Blaise, S. et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J. Rheumatol. 36, 984–988 (2009).
Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 41, 324–328 (2002).
Vancheeswaran, R., Azam, A. Black, C. & Dashwood, M. R. Localization of endothelin-1 and its binding sites in scleroderma skin. J. Rheumatol. 21, 1268–1276 (1994).
Pignone, A. et al. Reduced circulating levels of angiotensin-(1–7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann. Rheum. Dis. 66, 1305–1310 (2007).
Zamora, M. R. O'Brien R. F., Rutherford, R. B. & Weil, J. V. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 336, 1144–1147 (1990).
Campbell, P. M. & LeRoy, E. C. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin. Arthritis Rheum. 4, 351–368 (1975).
Rodnan, G. P., Myerowitz, R. L. & Justh, G. O. Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 59, 393–408 (1980).
Hasegawa, M., Nagai, Y., Tamura, A. & Ishikawa, O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br. J. Dermatol. 155, 1159–1164 (2006).
Ho, M., Veale, D., Eastmond, C., Nuki, G. & Belch, J. Macrovascular disease and systemic sclerosis. Ann. Rheum. Dis. 59, 39–43 (2000).
Fleming, J. N. & Schwartz, S. M. The pathology of scleroderma vascular disease. Rheum. Dis. Clin. North Am. 34, 41–55 (2008).
Kahaleh, B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum. Dis. Clin. North Am. 34, 57–71 (2008).
Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 452–460 (2010).
Laplante, P. et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J. Immunol. 174, 5740–5749 (2005).
Rajkumar, V. S. et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113–R1123 (2005).
Kuwana, M., Okazaki, Y., Yasuoka, H., Kawakami, Y. & Ikeda, Y. Defective vasculogenesis in systemic sclerosis. Lancet 364, 603–610 (2004).
Manetti, M. et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ. Res. 109, e14–e26 (2011).
Bukhari, M., Herrick, A. L., Moore, T., Manning, J. & Jayson, M. I. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br. J. Rheumatol. 35, 1127–1131 (1996).
Hirschl, M. et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum. 54, 1974–1981 (2006).
Chikura, B., Moore, T., Manning, J., Vail, A. & Herrick, A. L. Sparing of the thumb in Raynaud's phenomenon. Rheumatology (Oxford) 47, 219–221 (2008).
Bunker, C. B., Terenghi, G., Springall, D. R., Polak, J. M. & Dowd, P. M. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 336, 1530–1533 (1990).
Coffman, J. D. & Cohen, R. A. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur. J. Clin. Invest. 18, 309–313 (1988).
Flavahan, N. A., Cooke, J. P., Shepherd, J. T. & Vanhoutte, P. M. Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs. J. Pharmacol. Exp. Ther. 241, 361–365 (1987).
Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D. &, Flavahan, N. A. Silent α(2c)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am. J. Physiol. Heart. Circ. Physiol. 278, H1075–H1083 (2000).
Flavahan, N. A. et al. Increased α2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 43, 1886–1890 (2000).
Jeyaraj, S. C. et al. Cooling evokes redistribution of α2c-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol. Pharmacol. 60, 1195–1200 (2001).
Bailey, S. R., Eid, A. H., Mitra, S., Flavahan, S. & Flavahan, N. A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of α2C-adrenoceptor translocation. Circ. Res. 94, 1367–1374 (2004).
Bailey, S. R., Mitra, S., Flavahan, S. & Flavahan, N. A. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H243–H250 (2005).
Flavahan, N. A. Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. Rheum. Dis. Clin. North Am. 34, 81–87 (2008).
Yamazaki, F. Local ascorbate administration inhibits the adrenergic vasoconstrictor response to local cooling in the human skin. J. Appl. Physiol. 108, 328–333 (2010).
Furspan, P. B., Chatterjee, S. & Freedman, R. R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 50, 1578–1585 (2004).
Furspan, P. B., Chatterjee, S., Mayes, M. D. & Freedman, R. R. Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology (Oxford) 44, 488–494 (2005).
Stephens, D. P., Saad, A. R., Bennett, L. A., Kosiba, W. A. & Johnson, J. M. Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. Am. J. Physiol. Heart Circ. Physiol. 287, H1404–H1409 (2004).
Ames, P. R. et al. The coagulation/fibrinolytic balance in systemic sclerosis: evidence for a haematological stress syndrome. Br. J. Rheumatol. 36, 1045–1050 (1997).
Fatini, C. et al. Hemorheologic profile in systemic sclerosis: role of NOS3 -786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. Arthritis Rheum. 54, 2263–2270 (2006).
Postlethwaite, A. E. & Chiang, T. M. Platelet contributions to the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 19, 574–579 (2007).
Pamuk, G. E. et al. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul. Fibrinolysis 18, 297–302 (2007).
Kallenberg, C. G., Vallenga, E., Wouda, A. A. & The, T. H. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J. Rheumatol. 9, 878–884 (1982).
Lau, C. S. et al. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br. J. Rheumatol. 31, 375–380 (1992).
Solanilla, A. et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology (Oxford) 48, 1036–1044 (2009).
Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961–972 (2011).
Gabrielli, A. et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin. Immunopathol. 30, 329–337 (2008).
Freedman, R. R. & Mayes, M. D. Familial aggregation of primary Raynaud's disease. Arthritis Rheum. 39, 1189–1191 (1996).
Susol, E. et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum. 43, 1641–1646 (2000).
Frech, T. et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthritis Rheum. 62, 2109–2116 (2010).
Eid, A. H. et al. Estrogen increases smooth muscle expression of α2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 293, H1955–H1961 (2007).
Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902–3912 (2008).
Cutolo, M., Pizzorni, C. & Sulli, A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl. et al. Arthritis Rheum. 56, 2102–2103 (2007).
LeRoy, E. C. & Medsger, T. A. Raynaud's phenomenon: a proposal for classification. Clin. Exp. Rheumatol. 10, 485–488 (1992).
Chikura, B., Moore, T., Manning, J., Vail, A. & Herrick, A. L. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J. Rheumatol. 37, 783–786 (2010).
Wigley, F. M. Raynaud's phenomenon. N. Engl. J. Med. 347, 1001–1008 (2002).
Anderson, M. E., Moore, T. L., Lunt, M. & Herrick, A. L. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Rheumatology (Oxford) 6, 533–538 (2007).
Darton, K. & Black, C. M. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon. Br. J. Rheumatol. 30, 190–195 (1991).
O'Reilly, D., Taylor, L., el-Hadidy. K. & Jayson, M. I. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. Ann. Rheum. Dis. 51, 1193–1196 (1992).
Maricq, H. R. & LeRoy, E. C. Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy. Arthritis Rheum. 16, 619–628 (1973).
Herrick, A. L. & Cutolo, M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 62, 2595–2604 (2010).
Baron, M. et al. Office capillaroscopy in systemic sclerosis. Clin. Rheumatol. 26, 1268–1274 (2007).
Cutolo, M., Sulli, A. & Smith, V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat. Rev. Rheumatol. 6, 578–587 (2010).
Smith, V. et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann. Rheum. Dis. 69, 1092–1096 (2010).
Ingegnoli, F. et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology (Oxford) 49, 797–805 (2010).
Sebastiani, M. et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 61, 688–694 (2009).
Smith, V. et al. Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann. Rheum. Dis. 70, 180–183 (2011).
Matucci-Cerinic, M. et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann. Rheum. Dis. 68, 1377–1380 (2009).
Avouac, J. et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann. Rheum. Dis. 70, 476–481 (2011).
Murray, A., Herrick, A. L. & King, T. A. Laser Doppler imaging: a developing technique for application in the rheumatic diseases. Rheumatology (Oxford) 43, 1210–1218 (2004).
Herrick, A. L. & Clark, S. Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. Ann. Rheum. Dis. 57, 70–78 (1998).
Murray, A. K. et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum. 61, 1103–1111 (2009).
Korn, J. H. et al. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985–3993 (2004).
Chung, L. et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon. Arthritis Rheum. 60, 870–877 (2009).
Matucci-Cerinic, M. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 70, 32–38 (2011).
Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620–628 (2009).
Thompson, A. E. & Pope, J. E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44, 145–150 (2005).
Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841–1847 (2001).
Herrick, A. Raynaud's phenomenon (secondary). Clinical Evidence (Online) 2008, 1125 (2008).
Dziadzio, M. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646–2655 (1999).
Gliddon, A. E. et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 56, 3837–3846 (2007).
Harding, S. E. et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000956. http://dx.doi.org/10.1002/14651858.CD000956.
Coleiro, B. et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40, 1038–1043 (2001).
Wigley, F. M. et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann. Intern. Med. 120, 199–206 (1994).
Pope, J. et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews Issue 2. Art. No.: CD000953 http://dx.doi.org/10.1002/14651858.CD000953.
Fries, R., Shariat, K., von Wilmowsky, H. & Bohm, M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 112, 2980–2985 (2005).
Caglayan, E. et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch. Intern. Med. 166, 231–233 (2006).
Schiopu, E. et al. Randomised placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J. Rheumatol. 36, 2264–2268 (2009).
Shenoy, P. D. et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49, 2420–2428 (2010).
Herrick, A. L. et al. Modified-Release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 63, 775–782 (2011).
Herrick, A. L. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr. Opin. Rheumatol. 23, 555–561 (2011).
Brueckner, C. S. et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann. Rheum. Dis. 69, 1475–1478 (2010).
Dhaun, N., Pollock, D. M., Goddard, J. & Webb, D. J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol. Sci. 28, 573–579 (2007).
Bose, N. et al. Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging [abstract]. Arthritis Rheum. 62 (Suppl.), S239–S240 (2010).
Tomaino, M. M., Goitz, R. J. & Medsger, T. A. Surgery for ischemic pain and Raynaud's phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery. 21, 75–79 (2001).
Hartzell, T. L., Makhni, E. C. & Sampson, C. Long-term results of periarterial sympathectomy. J. Hand Surg. Am. 34, 1454–1460 (2009).
Kuwana, M. et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum. 54, 1946–1951 (2006).
Furukawa, S. et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann. Rheum. Dis. 65, 1118–1120 (2006).
Louneva, N., Huaman, G., Fertala, J. & Jimenez, S. A. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 54, 1298–1308 (2006).
Derk, C. T. & Jimenez, S. A. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun. Rev. 5, 25–32 (2006).
Abou-Raya, A., Abou-Raya, S. & Helmii. M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J. Rheumatol. 35, 1801–1808 (2008).
Fishman, A. P. Pulmonary hypertension—beyond vasodilator therapy. N. Engl. J. Med. 338, 321–322 (1998).
Chrysant, S. G. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am. Heart J. 135, S21–S30 (1998).
Kirchengast, M. & Munter, K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc. Soc. Exp. Biol. Med. 221, 312–325 (1999).
Shenoy, P. & Agarwal, V. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun. Rev. 9, 511–515 (2010).
Kleckner, M. Jr, Allen, E. V. & Wakim, K. G. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: studies on blood flow and clinical manifestations. Circulation. 3, 681–689 (1951).
Teh, L. S. et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br. J. Rheumatol. 34, 636–641 (1995).
Wigley, F. M. et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 41, 670–677 (1998).
Seibold, J. R. et al. Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: a randomized, double-blind, placebo-controlled, multicenter study (abstract). Arthritis Rheum. 63 (Suppl.), S968–S969 (2011).
Van Beek, A. L, Lim, P. K, Gear, A. J. & Pritzler, M. R. Management of vasospastic disorders with botulinum toxin A. Plast. Reconstr. Surg. 119, 217–226 (2007).
Neumeister, MW. et al. Botox therapy for ischemic digits. Plast. Reconstr. Surg. 124, 191–201 (2009).
Wise, R. A. et al. Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 50, 3994–4001 (2004).
Fava, A. et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res. 64, 925–929 (2012).
The author declares that she has been a consultant for and received honoraria from Actelion and Pfizer. She has also been an investigator in clinical trials supported by Actelion, MediQuest, Orion Pharma and United Therapeutics.
Rights and permissions
About this article
Cite this article
Herrick, A. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 8, 469–479 (2012). https://doi.org/10.1038/nrrheum.2012.96
This article is cited by
Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series
Pediatric Rheumatology (2022)
Serum vitamin B12 and D levels in children with Primary Raynaud Phenomenon: a retrospective cohort study
European Journal of Clinical Nutrition (2022)
Nailfold capillaroscopy: tips and challenges
Clinical Rheumatology (2022)
Structural abnormalities associated with glaucoma using swept-source optical coherence tomography in patients with systemic sclerosis
International Ophthalmology (2022)
A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis
Clinical Reviews in Allergy & Immunology (2022)